The short version of Fragment designation fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
=== Adhesive organ === On the terminal region of the 5th tarsal segment, the C. vomitoria contain pulvilli, which are the cushion-like hairy feet on insects and many arthropods located at base of their two claws. The hair that project from the ventral surface is the key for the adhesion abilities of these flies. Additionally, they have large claws that help to hold on to irregular surfaces to prevent falling. Calliphora vomitoria, like other blowflies, also secrete non-volatile lipids through the hairs that are important for further adhesion. By a combination of the physical grip of the claws and hairs and the surface tension created by the lipid secretions, they are able to adhere to smooth surfaces with ease.
==== In Greater Russia ==== At the outbreak of the disorder on 8 March 1917 that led to the overthrow of the tsarist regime, approximately 3,200 Cossacks from the Don, Kuban, and Terek Hosts were stationed in Petrograd. Although they comprised only a fraction of the 300,000 troops in the proximity of the Russian capital, their general defection on the second day of unrest (10 March) enthused raucous crowds and stunned the authorities and remaining loyal units. In the aftermath of the February Revolution, the Cossacks hosts were authorized by the War Ministry of the Russian Provisional Government to overhaul their administrations. Cossack assemblies (known as krugs or, in the case of the Kuban Cossacks, a rada) were organized at regional level to elect atamans and pass resolutions. At national level, an all-Cossack congress was convened in Petrograd. This congress formed the Union of Cossack Hosts, ostensibly to represent the interests of Cossacks across Russia. During the course of 1917, the nascent Cossack governments formed by the krugs and atamans increasingly challenged the Provisional Government's authority in the borderlands. The various Cossack governments themselves faced rivals, in the form of national councils organized by neighboring minorities, and of soviets and zemstvos formed by non-Cossack Russians, especially the so-called "outlanders" who had immigrated to Cossack lands.
MgO·CaO +Si → 2 Mg + Ca2SiO4 The calcium oxide combines with silicon as the oxygen scavenger, yielding the very stable calcium silicate. The Mg/Ca ratio of the precursors can be adjusted by the addition of MgO or CaO. The Pidgeon and the Bolzano process differ in the details of the heating and the configuration of the reactor. Both generate gaseous Mg that is condensed and collected. The Pidgeon process dominates the worldwide production. The Pidgeon method is less technologically complex and because of distillation/vapour deposition conditions, a high purity product is easily achievable. China is almost completely reliant on the silicothermic Pidgeon process.
== External links == Clinical trial number NCT04020341 for "A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)" at ClinicalTrials.gov Clinical trial number NCT04187144 for "Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)" at ClinicalTrials.gov
Sources: en.wikipedia.org
Sulfadimidine or sulfamethazine is a sulfonamide antibacterial. There are non-standardizeda abbreviations for it as "sulfadimidine" (abbreviated SDI and more commonly but less reliablyb SDD) and as "sulfamethazine" (abbreviated SMT and more commonly but less reliablyc SMZ). Other names include sulfadimerazine, sulfadimezine, and sulphadimethylpyrimidine.
One NADH molecule is produced by the enzyme glutamate dehydrogenase in the conversion of glutamate to ammonium and α-ketoglutarate. Glutamate is the non-toxic carrier of amine groups. This provides the ammonium ion used in the initial synthesis of carbamoyl phosphate. The fumarate released in the cytosol is hydrated to malate by cytosolic fumarase. This malate is then oxidized to oxaloacetate by cytosolic malate dehydrogenase, generating a reduced NADH in the cytosol. Oxaloacetate is one of the keto acids preferred by transaminases, and so will be recycled to aspartate, maintaining the flow of nitrogen into the urea cycle. We can summarize this by combining the reactions:
1993/29) Income Support (General) Amendment Regulations 1993 (S.I. 1993/30) Motor Vehicles (Wearing of Seat Belts by Children in Front Seats) Regulations 1993 (S.I. 1993/31) Food Protection (Emergency Prohibitions) (Radioactivity in Sheep) (Wales) (Partial Revocation) Order 1993 (S.I. 1993/32) Food Protection (Emergency Prohibitions) (Radioactivity in Sheep) (England) (Partial Revocation) Order 1993 (S.I. 1993/33) North West London Mental Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/34) Road Traffic Regulation Act 1984 (Amendment) Order 1993 (S.I. 1993/35) Local Authorities (Discretionary Expenditure) (Relevant Population) Regulations 1993 (S.I. 1993/40) Local Authorities (Discretionary Expenditure Limits) Order 1993 (S.I. 1993/41) Control of Pollution (Anglers' Lead Weights) (Amendment) Regulations 1993 (S.I. 1993/49) Gipsy Encampments (London Borough of Bromley) Order 1993 (S.I. 1993/50) Licensed Betting Offices (Amendment) Regulations 1993 (S.I. 1993/51) Combined Probation Areas (Powys) Order 1993 (S.I. 1993/52) National Rivers Authority (Anglian Region) (Reconstitution of the Alford Drainage Board) Order 1992 S.I. 1993/53) National Rivers Authority (Anglian Region) (Reconstruction of the North East Lindsey Internal Drainage Board) Order 1992 S.I. 1993/54) National Rivers Authority (Anglian Region) (Reconstitution of the Louth Drainage Board) Order 1992 S.I. 1993/55) Education (Higher Education Corporations) (Wales) (No. 3) Order 1993 (S.I. 1993/56) Friendly Societies (Group Schemes) Regulations 1993 (S.I.
Sources: en.wikipedia.org
== Evolution == CHS belongs to a broader class of enzymes known as type III PKSs. Being the first enzyme of its type to be discovered, all other members are often labeled as “CHS-like.” Most or all of the divergent CHS-like enzymes characterized have arisen from extensive duplication and subsequent genetic variation of the chs gene. Duplication provides CHS activity with functional redundancy, allowing the chs gene to mutate without endangering flavonoid biosynthesis. These divergent enzymes differ from CHS in their preference for starter molecules, the number of acetyl additions (often through malonyl-CoA) and even in the mechanism of ring formation used to cyclize identical polyketide intermediates. The enzyme function of CHS and CHS-like enzymes function very similarly to fatty acid biosynthesis, but without the involvement of acyl-carrier proteins (ACP). Structural evidence suggests that these enzymes emerged by gain of function from ketoacyl synthase (KAS) III, an early stage enzyme of type II fatty acid biosynthesis. Although higher plant chalcone synthases have been extensively studied, little information is available on the enzymes from bryophytes (primitive plants). Cloning of CHS from the moss Physcomitrella patens revealed an important transition from the chalcone synthases present in microorganisms to those present in higher plants.
== Operations == Unichem's Formulations manufacturing facilities are located at Goa, Ghaziabad (Uttar Pradesh) and Baddi (Himachal Pradesh). Active Pharmaceutical Ingredient (API) manufacturing facilities are located at Roha (Maharashtra), Pithampur (Madhya Pradesh) and Kolhapur (Maharashtra). Goa, Ghaziabad, Roha, Pithampur and Kolhapur sites are USFDA approved and all the plants are approved from other major health authorities. The Company's facilities have been approved by various International health authorities such as USFDA, UK MHRA, ANVISA (Brazil), COFEPRIS (Mexico), PMDA (Japan), TGA (Australia), SAPHRA (South Africa) and MFDS(Korea), EDQM (European Directorate for the Quality of Medicines), TPD (Canada).
Alfred Guillou Redfield (March 11, 1929 – July 24, 2019) was an American physicist and biochemist. In 1955 he published the Redfield relaxation theory, effectively moving the practice of NMR or Nuclear magnetic resonance from the realm of classical physics to the realm of semiclassical physics. He is known for the development of Redfield equation. He continued to find novel magnetic resonance applications to solve real-world problems throughout his life. Redfield earned degrees at Harvard College (BA 1950, Master's 1952) and the University of Illinois, Urbana-Champaign (Ph.D. 1953). As a postdoc, he worked with Nicolaas Bloembergen at Harvard, where he first published the Redfield relaxation theory. IBM Watson Scientific Computing Laboratory hired him in 1955 and he taught at Columbia. While there, he published his most important work, the Redfield Relaxation Equation. In 1971 he published experiments that helped to draw the veil of H₂O molecules away from hitherto invisible atoms in large, biological molecules. He continued to innovate specific NMR techniques to view the molecular structure of nucleic acids and enzymes. Beginning in 1996, the NMR Field Cycling community began to realize that slow NMR had an advantage over X-ray crystallography for observing large, biological molecule (macromolecule) dynamics, which can't be captured by high-energy NMR or crystallography. In 1996 he released an article exploring field cycling as a way to study macromolecules in more detail. He published his first article using the phosphorus isotope 31P to probe phospholipids in 2004.
=== Cardiac rhythm disease management === Cardiac rhythm disease management (CRDM) is the oldest and largest of Medtronic's business units. Its work in heart rhythm therapies dates back to 1957 when Bakken developed the first wearable heart pacemaker to treat abnormally slow heart rates. Since then, it has expanded its expertise in electrical stimulation to treat other cardiac rhythm diseases. It has also made an effort to address overall disease management by adding diagnostic and monitoring capabilities to many of its devices. An independently-operating Dutch pacemaker manufacturer, Vitatron, acquired by Medtronic in 1986, is now a European subsidiary of the unit. Medtronic and Vitatron pacemakers are interrogated and programmed by Medtronic Carelink Model 2090 Programmer for Medtronic and Vitatron Devices; they use separate interfaces. In 2007, Medtronic recalled its Sprint Fidelis product, the flexible wires, or leads, which connect a defibrillator to the interior of the heart. The leads were found to be failing at an unacceptable rate, resulting in unnecessary shocks or no shocks when needed; either can be lethal. The scope of the problem continues to be a matter of research. Studies since the recall, disputed by Medtronic, suggest that the failure rate of already-implanted Sprint Fidelis leads is increasing exponentially. Medtronic's liability is limited by various court decisions.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.